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Panhofer P, Gleiss A, Eilenberg WH, et al. Br J Surg 2013;100:1471-7.
Conclusions: T4 endothoracic sympathetic clip application is effective
and safe for treatment of patients with upper limb hyperhidrosis, particularly
for those with isolated palmar hyperhidrosis but also to a lesser extent for
those with combined palmoaxillary hyperhidrosis.
Summary: Endothoracic sympathectomy has been established as an
effective and safe therapeutic option for patients with primary upper ex-
tremity hyperhidrosis. The major drawback, however, is compensatory
sweating. Limited intervention at the fourth thoracic ganglion (T4) should
result in lower levels of compensatory sweating in patients treated for upper
limb hyperhidrosis. Preservation of inhibitory reﬂex mechanisms above T4
inhibits increased sweating from other body regions (Lin CC et al, Ann
Chir Gynaecol 2001;90:161-6). In this study, the authors sought to eval-
uate long-term outcomes of endothoracic sympathetic block at T4
(EST4). Special emphasis was placed on evaluation of disease-speciﬁc qual-
ity of life (QoL) through review of a prospectively accumulated database.
This was a prospective study conducted at a university hospital where pa-
tients treated with EST4 for palmar or palmoaxillary hyperhidrosis between
2001 and 2008 were evaluated. Questionnaires were developed by Keller
and Milanez de Campos to evaluate disease-speciﬁc QoL. There were
374 EST4 procedures performed in 189 patients. Of 174 evaluated pa-
tients, 54 (31.0%) had palmar and 120 (69.0%) had palmoaxillary hyperhi-
drosis. Median follow-up was 92 months. EST4 successfully reduced
hyperhidrosis in both groups (P < .001) and improved QoL (P < .001).
Improvement remained stable after 5 years. However, the overall satisfac-
tion rate did decrease secondary to the development of compensatory
sweating and recurrence during follow-up. Compensatory sweating
affected 41 patients (23.6%) and was severe in 11 of the 163 patients
(6.7%) with 5-year follow-up. Severity of compensatory sweating did not
further worsen with time, but occurrence of severe hyperhidrosis increased
to 11% at the end of follow-up. Severe compensatory sweating was twice as
common in patients treated for palmoaxillary sweating than those treated
for palmar sweating (13.2% vs 6.1%).
Comment: The most irritating side effect after upper extremity sym-
pathectomy is compensatory sweating. In such cases, sweating is activated
by stressors such as physical examination, heat, and psychologic stress. How-
ever, no patient in this study apparently considered the compensatory sweat-
ing, even when “severe” to be intolerable. Although there are other
therapies for severe hyperhidrosis, such as botulinum toxin injections and
axillary sweat gland aspiration, overall endoscopic sympathectomy at T4
seems to result in both favorable and durable clinical outcomes, particularly
for patients with palmar hyperhidrosis, but to a lesser extent, for those with
combined palmoaxillary hyperhidrosis as well.
Predicting Aortic Complications After Endovascular Aneurysm Repair
KarthikesalingamA,Holt PJ,Vidal-DiezA, et al.Br J Surg2013;100:1302-11.
Conclusion: A risk score using commonly available morphologic data
stratiﬁes the rate of complications after endovascular aneurysm repair
(EVAR).
Summary: Lifelong surveillance is recommended as standard of care
after EVAR (Moll FL et al, Eur J Vasc EndovascSurg 2011;41:S1-58).
There is, however, no consensus on optimal surveillance protocols after
EVAR. Optimizing surveillance is a priority because surveillance protocols
may inﬂuence the long-term cost effectiveness of EVAR and have obvious
clinical importance (Chambers D et al, Health Technol Assess 2009;13:1-
189). It also appears the risk of endograft failure after EVAR is not equally
distributed among all patients, and there may be a minority of patients at
greater risk of complications. This increased risk of complications appears
to be deﬁned by aneurysm morphology rather than by physiology or patient
comorbidity (Patterson BO et al, J Vasc Surg 2010;52:25-30). In this study,
the authors sought to determine which morphologic features predict the
development of aortic complications after EVAR. They also sought to
develop and validate a predictive risk score for aortic complications after
EVAR. The study involved patients undergoing EVAR at two centers
from 2004 to 2010. Preoperative aneurysm morphology was quantiﬁed us-
ing three-dimensional computed tomography scanning according to a vali-
dated protocol. Morphology was determined by investigators blinded to
outcomes. Proportional hazards models were used to identify factors pre-
dicting aortic complications at the ﬁrst center, and a risk score was then
developed. Sidak tests between risk quartiles dichotomized patients to
low-risk or high-risk groups. Aortic complications were reported by
Kaplan-Meier analysis, and risk groups were compared by log-rank test.
External validation was by comparison of aortic complications between
risk groups at the second center. There were 761 patients with a medianage of 75 years who underwent EVAR. Median follow-up was 36 months
(range, 11-94 months). Physiologic variables were not associated with aortic
complications. A morphologic risk score incorporating maximum aneurysm
diameter (P < .001) and the largest common iliac diameter measured 10
mm from the internal iliac origin (P ¼ .004) allocated 75% of patients to
a low-risk group. There was excellent discrimination between 5-year rates
of aortic complications in low-risk and high-risk groups at both centers
(center 1: 12% vs 31%, P < .001; center 2: 12% vs 45%, P ¼ .002).
Comment: The study describes a simple risk score for predicting com-
plications after EVAR. There are several limitations, including that the risk
score has not been validated outside of the two participating centers and
that most of the devices in this study were Cook Zenith endografts, so val-
idity of the risk score for other devices will require additional conﬁrmation.
Urgent Best Medical Therapy May Obviate the Need for Urgent
Surgery in Patients With Symptomatic Carotid Stenosis
Shahidi S, Owen-Falkenberg A, Hjerpsted U, et al. Stroke 2013;44:2220-5.
Conclusions: Carotid endarterectomy (CEA) can be performed in
the subacute period without signiﬁcantly increasing operative risk. Urgent
best medical treatment is associated with a signiﬁcant reduction in risk of
early neurologic recurrence in CEA patients.
Summary: Current guidelines from the European Vascular Surgical
Society, the United Kingdom National Institute for Clinical Excellence,
and the American Heart Association all recommend that CEA should be
performed #14 days of onset of neurologic symptoms in patients with
>50% symptomatic ipsilateral carotid artery stenosis. It has been calculated
that performing subacute CEA #2 weeks in patients with symptomatic 50%
to 99% stenosis (North American Symptomatic Carotid Endarterectomy
Trial) and 70% to 99% stenosis (European Carotid Surgery Trial) will pre-
vent 185 ipsilateral disabling strokes per 1000 CEAs at 5 years. The number
needed to treat is six. In contrast, only eight strokes will be prevented in 5
years if surgery is delayed by >12 weeks and the number needed to treat is
125 (Rothwell PM et al, Lancet 2004;363:915-24, and Naylor AR Surgeon
2007;5:23-30). This study examines the effect of introducing a rapid-access
carotid surgery service with focus on the effects of delays for surgery, proce-
dural risk of CEA, and effective best medical treatment on recurrent neuro-
logic symptoms. This is a prospective population-based study of delays to
CEA and 30-day outcomes in patients with symptomatic carotid stenosis.
Neurologic recurrence (NR) rate was determined after initiation of best
medical treatment consisting of a loading dose of aspirin/clopidogrel, fol-
lowed by duel therapy with aspirin and clopidogrel and a statin until the
time of CEA. The NR #90 days before the index event was also assessed.
There were 4905 patients with transient ischemic attacks/ischemic stroke
and ocular events. Of these, 115 symptomatic patients underwent CEA,
42% #14 days of the index event and 99% #14 days of surgical referral.
The overall NR from index event to CEA in symptomatic carotid stenosis
patients was lower (2.5% [95% conﬁdence interval, 1%-6%]) with best med-
ical treatment compared with NR #90 days in patients before referral to a
stroke clinic and institution of best medical management (29% [95% conﬁ-
dence interval, 22%-37%]; P < .00001). There were no strokes or death
#30 days after CEA and no signiﬁcant differences in outcomes among
48 early (<14 days), 46 intermediate (14-30 days), and 21 delayed (>30
days) CEAs.
Comment: The “control” group in this series consisted of patients
who basically had a small stroke or TIA or ocular event and who did not
go to the doctor until they had the second event. Because they did not
go to the doctor, they did not receive “best medical therapy.” The study
group were those who went to the doctor after their initial event and did
receive a combination of aspirin and clopidogrel and a statin. Obviously,
there may be unrecognized confounding variables in patients who go the
doctor after a neurologic event vs those who wait for a second or third
event. No patient underwent CEA on the weekend or #2 days of a neuro-
logic event. The data suggest institution of immediate best medical manage-
ment of aspirin, clopidogrel, and statin, followed by early but not necessarily
emergency CEA, is a reasonable course of action in the patient with high-
grade symptomatic carotid stenosis.
Drug-Eluting Balloon in Peripheral Intervention for Below the Knee
Angioplasty Evaluation (DEBATE-BTK): A Randomized Trial in
Diabetic Patients With Critical Limb Ischemia
Liistro F, Porto I, Angioli P, et al. Circulation 2013;128:615-21.
Conclusions: Compared with percutaneous transluminal angioplasty
(PTA) alone, use of drug-eluting balloons for angioplasty of infrapopliteal
arteries results in signiﬁcantly higher tibial artery patency, with reductions
